Alectinib is indicated for:
Irrespective of gender only Adults (18 years old or older)
Alectinib as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
Alectinib as monotherapy is indicated for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.
For this indication, the medical literature mentions below treatments (click for details):
Active ingredient Alectinib is contraindicated in the following cases: